Optimizing Care in Relapsed/Refractory Multiple Myeloma Through Pharmacist Interventions: A Focus on BCMA-Directed Therapies

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

The treatment of multiple myeloma (MM) is rapidly evolving, as novel therapies and combinations of therapies are now recommended in national clinical practice guidelines. The B-cell maturation antigen (BCMA) plays a key role in MM, as it is overexpressed and activated. Drug therapies are now available that target BCMA specifically and are recommended in clinical guidelines for treating relapsed or refractory MM. This activity will review the clinical data for BCMA therapies in MM and will also explore the role of the pharmacist in mitigating adverse effects associated with these agents.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 15, 2022
Expiration date: April 15, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the role of B-cell maturation antigen (BCMA) as a therapeutic target for relapsed/refractory multiple myeloma (RRMM)
• Apply new and emerging clinical data in the selection of a BCMA-targeted treatment strategy for a patient with RRMM
• Explore strategies to minimize and/or manage adverse effects associated with BCMA-directed therapies for the treatment of RRMM

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-162-H01-P. The activity is available for CE credit through April 15, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Joseph A. Kalis, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: GSK, Oncopeptides

Kirollos S. Hanna, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Seagen, AbbVie

Speakers Bureau: Seagen, AbbVie, BMS, BeiGene, Exelixis, Rigel, Sanofi, GSK

Rebecca Nelson, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: AbbVie, Amgen, BTG, Sanofi, Stemline, TG

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms